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Dystrophin quantification
Biological and translational research implications
ABSTRACT
Objective: We formed a multi-institution collaboration in order to compare dystrophin quantifica-
tion methods, reach a consensus on the most reliable method, and report its biological signifi-
cance in the context of clinical trials.
Methods: Five laboratories with expertise in dystrophin quantification performed a data-driven
comparative analysis of a single reference set of normal and dystrophinopathy muscle biopsies
using quantitative immunohistochemistry and Western blotting. We developed standardized
protocols and assessed inter- and intralaboratory variability over a wide range of dystrophin
expression levels.
Results: Results from the different laboratories were highly concordant with minimal inter- and in-
tralaboratory variability, particularly with quantitative immunohistochemistry. There was a good
level of agreement between data generated by immunohistochemistry and Western blotting,
although immunohistochemistry was more sensitive. Furthermore, mean dystrophin levels deter-
mined by alternative quantitative immunohistochemistry methods were highly comparable.
Conclusions: Considering the biological function of dystrophin at the sarcolemma, our data
indicate that the combined use of quantitative immunohistochemistry and Western blotting are
reliable biochemical outcome measures for Duchenne muscular dystrophy clinical trials, and that
standardized protocols can be comparable between competent laboratories. The methodology
validated in our study will facilitate the development of experimental therapies focused on dystro-
phin production and their regulatory approval. Neurology® 2014;83:2062–2069
GLOSSARY
BMD 5 Becker muscular dystrophy; BOM-SG 5 biochemical outcome measures study group; CV 5 coefficient of variation;
DMD 5 Duchenne muscular dystrophy; IgG 5 immunoglobulin G; PBS 5 phosphate-buffered saline.
Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disorder caused by mu-
tations in theDMD gene, which prevent the expression of its product, dystrophin.1,2 The milder
Becker muscular dystrophy (BMD) is also caused by DMD mutations that result in variable
expression of a shorter dystrophin.1–5 Therapeutic interventions aimed at restoring dystrophin
expression are in clinical trials.6–14 Dystrophin quantification is an essential biochemical out-
come measure for these trials. However, the absence of a reference standard, the large size and
low expression of the protein, combined with preexisting dystrophin-positive revertant fibers
and residual trace dystrophin,15 make accurate quantification challenging, especially when the
amount of restored dystrophin is small.15,16 Because regulatory authorities previously indicated
that lack of consensus on the standardized methodology was an obstacle to the advancement of
the field,17 a group of laboratories from academia and industry formed a biochemical outcome
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measures study group (BOM-SG) to provide
a data-driven reproducible methodology for
dystrophin quantification. In a pilot study
comparing the sensitivity and reliability of
the preferred individual laboratories’ method-
ologies, we found significant levels of inter-
and intralaboratory variability (data not
shown). Herein, we present a controlled anal-
ysis of proposed standard operating procedures
for quantitative immunohistochemistry and
Western blotting for evaluation of dystrophin
expression. We discuss the biological signifi-
cance of our data in the context of dystrophic
muscle pathology. We demonstrate that data
from different laboratories can be comparable,
thus validating immunohistochemistry and
Western blotting as biochemical biomarkers
for DMD clinical trials.
METHODS Five laboratories of the BOM-SG (The Dubowitz
Neuromuscular Centre, UCL Institute of Child Health, London,
UK; the Flanigan laboratory at the Center for Gene Therapy,
Nationwide Children’s Hospital, Columbus, OH; Institute of
Genetic Medicine, Newcastle University, UK; Institut de
Myologie, UPMC UM76, INSERM U 794, CNRS UMR
7215, Paris, France; and Prosensa Therapeutics, Leiden, the
Netherlands) performed blinded analysis of the same set of
muscle biopsies (control [n 5 2], DMD [n 5 3], and BMD
[n 5 3]) (table 1) using standardized immunohistochemistry
and Western blotting protocols.
Standard protocol approvals, registrations, and patient
consents. We obtained written informed consent for the use of
archived muscle tissues from all patients or guardians (as appro-
priate) under a protocol approved by the Nationwide Children’s
Hospital institutional review board. The studies at Great
Ormond Street Hospital were performed under approval by the
National Research Ethics Committee (05/MRE12/32).
Muscle biopsies. We selected muscle biopsies previously
archived as part of the United Dystrophinopathy Project in the
Flanigan laboratory. All biopsies had been assessed for dystrophin
content on a clinical or research basis and were dispensed labeled
only with a blinded code, maintained in the Flanigan labora-
tory.18 Each laboratory received the same number of unfixed
frozen serial 10-mm transverse muscle sections on microscope
slides and an Eppendorf tube containing forty 10-mm sections
of frozen muscle tissue. All laboratories were informed of the
identity of the control biopsies.
Immunohistochemistry. The staining protocol, based on that
of Taylor et al.,18 was as follows:
• Transverse sections were air-dried at room temperature
for 20 to 30 minutes and circled with a hydrophobic
peroxidase-antiperoxidase pen.
• Primary dystrophin (rabbit C-terminal ab15277; Abcam,
Cambridge, MA) and spectrin (monoclonal NCL-SPEC1;
Leica Microsystems Inc., Buffalo Grove, IL) antibodies
were diluted (1:400 and 1:100, respectively) in
phosphate-buffered saline (PBS) and incubated with the
sections for 1 hour at room temperature.
• Sections were washed (33) in PBS for 3 minutes each.
• Each laboratory used secondary antibodies compatible with
their microscope, e.g., Alexa Fluor 488 goat anti-mouse
immunoglobulin G (IgG) (A11017; Molecular Probes,
Eugene, OR) and Alexa Fluor 568 goat anti-rabbit IgG
(A11036; Molecular Probes). These were diluted 1:500
in PBS and incubated for 30 minutes in the dark at room
temperature.
• Sections were washed (33) in PBS for 3 minutes.
• Slides were mounted using anti-fade mounting agent, e.g.,
ProLong Gold anti-fade reagent (Molecular Probes).
All laboratories measured dystrophin intensity using the
Arechavala-Gomeza method, which measures the fluorescent
intensity of 40 specific sarcolemmal regions of interest19 selected
manually at random. Each of these regions of interest includes
maximum and minimum intensity data points that are used in
the data analysis. In parallel, 3 laboratories (1, 4, and 5) also
quantified dystrophin using the Taylor method.18 This method
makes use of the double staining with spectrin, another sarcolem-
mal protein whose level is unaffected in dystrophinopathy mus-
cle, to create a mask that defines only the sarcolemmal area in
each image. This mask allows the measurement of the intensity of
the sarcolemmal area of the whole image.18 In addition, labora-
tory 4 used the Beekman method in which a spectrin mask is also
used to select the sarcolemma of each individual fiber of the
image.20 With this algorithm, the individual intensities of an
average of 350 fibers are measured and the mean dystrophin
intensity of the fiber population is calculated using Definiens
Table 1 Sample ranking order by laboratory
Immunohistochemistry Western blotting
Sample Lab 1 Lab 2 Lab 3 Lab 4 Lab 5 Sample Lab 1 Lab 2 Lab 3 Lab 4 Lab 5
A (BMD) 1 1 1 1 2 F (BMD) 1 1 1 1 1
F (BMD) 2 2 2 2 1 D (BMD) 2 3 2 3 2
D (BMD) 3 3 3 3 3 A (BMD) 3 2 3 2 3
C (DMD) 4 4 4 4 4 C (DMD) 4 4 4 4 4
E (DMD) 5 6 6 5 5 E (DMD) 5/6 5/6 5 5 5/6
B (DMD) 6 5 5 6 6 B (DMD) 5/6 5/6 6 6 5/6
Abbreviations: BMD 5 Becker muscular dystrophy; del 5 deletion; DMD 5 Duchenne muscular dystrophy; dup 5 duplication; ex 5 exon.
Samples: A 5 c.40_41delGA; B 5 dup ex 10–17; C 5 dup ex 7; D 5 del ex 3–27; E 5 del ex 6; F 5 del ex 10–44.
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software.20 The key difference between these methods relates to
the number of fibers measured per captured image. For a detailed
protocol of each method, see e-Methods on the Neurology® Web
site at Neurology.org.
Western blotting. The protocol, based on that of Taylor
et al.,18 was as follows:
• Samples were solubilized in lysis buffer (4.4 mM Tris, 9%
sodium dodecyl sulfate, 4% glycerol, 5%b-mercaptoethanol).
• Loading 25 mg of protein, each laboratory used their pre-
ferred gel electrophoresis (typically 3%–8% tris-acetate
gradient gels) and Western blotting equipment.
• Membranes were incubated with the anti-dystrophin pri-
mary antibody (ab15277) at 1 mg/mL overnight at 4°C in
5% milk TBS-T (TRIS buffered saline, 0.1% Tween20).
• A sarcomeric a-actinin primary antibody (Clone EA-53;
Sigma, St. Louis, MO) diluted at 1:3,000 in 5% milk
TBS-T was added and membranes were incubated for
1 hour at room temperature.
• Membranes were washed (33) for 10 minutes each in
PBS-T.
• Secondary antibodies compatible with the laboratories’ imag-
ing equipment were used, e.g., horseradish peroxidase–
conjugated goat anti-rabbit (1:15,000) and goat anti-mouse
IgG (1:500,000) were incubated with the membranes for
30 minutes at room temperature.
• Membranes were washed (33) for 10 minutes each in
TBS-T.
Each laboratory used their preferred image acquisition equip-
ment (e.g., Image J–based software, Odyssey infrared imaging
system); the data were normalized to a-actinin and presented
relative to an average of the 2 controls.
Statistical analysis. Experiments were performed in triplicate
and statistical analysis was performed using GraphPad Prism
version 5.03 (GraphPad Software, La Jolla, CA). The coefficient
of variation (CV) was calculated using the formula CV 5 SD/
mean 3 100. For intralaboratory analysis, the CV for each lab-
oratory for each biopsy was calculated (tables e-1 to e-6) and the
CVs from the 6 biopsies were averaged for each laboratory.
The Bland-Altman plot was used to assess the agreement
between different methods.21
RESULTS Each laboratory ranked the samples ac-
cording to the relative level of dystrophin expression
determined by each technique (table 1). There was
a high level of agreement among all laboratories for
both immunohistochemistry and Western blotting.
All laboratories identified the 3 BMD samples as hav-
ing the highest dystrophin protein levels, although
this top order differed between immunohistochemis-
try and Western blotting. By Western blot analysis,
no laboratory could detect dystrophin in sample B
and only 2 laboratories (3 and 4) could detect trace
amounts of dystrophin protein in sample E.
Inter- and intralaboratory variability of dystrophin
quantification using immunohistochemistry. From each
laboratory’s data (Arechavala-Gomeza19 method), we
calculated the mean (6SD) dystrophin levels of each
sample and the CV (figure 1). Overall, the level of
variability observed among the different laboratories
was minimal with an average SD of 7.78 (ranging
between 3.33 for sample E and 11.93 for
sample A). We calculated the CV for each sample
to statistically measure the degree of variation
between the laboratories. A CV value of less than
Figure 1 Inter- and intralaboratory variability of dystrophin quantification using immunohistochemistry
Five laboratories each quantified the level of dystrophin expression in the same 6 biopsies using a standardized immuno-
histochemistry protocol; data were analyzed using the Arechavala-Gomeza method.19 To assess interlaboratory variability,
the mean 6 SD for each biopsy was calculated as well as the coefficient of variation (CV). Note how this variation is higher
for those samples containing less dystrophin (E and B). To assess intraassay precision within each laboratory, the mean 6
SD for each laboratory per sample was calculated as well as the average CV per laboratory. Laboratories are unidentified.
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20% is considered optimal.22 The CV values averaged
33% (ranging between 23% for sample A and 67%
for sample B); samples A, C, D, and F had CV values
between 20% and 30%.
We next analyzed intralaboratory variability in the
same manner (figure 1). We calculated the average
CV value from each laboratory (see tables e-1 to e-6
for individual data). The CV values for immunohis-
tochemistry were below 30% for all laboratories, with
laboratories 4 and 5 having low CV values of 14%
and 14%, respectively.
While all laboratories were able to use the
Arechavala-Gomeza method,19 some laboratories
had access to software that enabled them to directly
compare this method with additional automated meth-
ods. Three laboratories (1, 4, and 5) analyzed the same
samples using the Taylor method and one laboratory (4)
compared 3 different methods (Arechavala-Gomeza,19
Taylor,18 and Beekman20 methods). We analyzed
the same images using the above intensity measure-
ment techniques and we assessed the level of agree-
ment between them by plotting the mean (6SD) of
each sample for all techniques (figure 2A). Next,
rather than calculate the correlation coefficient, which
can hide a considerable lack of agreement,23 we
plotted the data with a regression line, plotting the
more automated Taylor18 or Beekman20 methods
against the Arechavala-Gomeza19 method (figure
2B). We then selected the 2 methods used by more
than one laboratory (Arechavala-Gomeza19 and
Taylor18 methods), observed that the mean data from
the 2 techniques were essentially identical (figure 2, A
and B), and generated a Bland-Altman plot (figure
2C).23 This analysis shows that both methods are
equivalent: the bias (the difference between the
means) was only 2.103 and the 95% limits of agree-
ment were between 10.83 and 26.63.
Inter- and intralaboratory variability of dystrophin
quantification using Western blotting. We assessed the
level of inter- and intralaboratory variability observed
with Western blotting as above (figure 3). We
observed more variability with Western blotting than
immunohistochemistry with a mean SD of 15.95
(ranging between 0.89 for sample E and 33.09 for
sample F). The CV values for Western blotting aver-
aged 80% (ranging between 23% for sample F and
223% for sample E) confirming a higher degree of
variability with this technique; only samples D and F
had CV values nearing 20% (figure 3). The CV val-
ues were particularly affected by 2 of the samples
(B and E) being at/below the limit of sensitivity;
our results thus indicate that the interlaboratory var-
iability improves as the level of dystrophin increases.
Intralaboratory variability was also more pro-
nounced than for immunohistochemistry. Only labo-
ratory 1 had an optimal CV value of 0.3%; laboratory
3 had the highest at 119% (figure 3).
Immunohistochemistry and Western blotting data
comparison. To assess the level of agreement between
the immunohistochemistry and Western blotting
data, we plotted the mean (6SD) of each sample
for both techniques (figure 4A), plotted the data with
a regression line (figure 4B), and generated a Bland-
Altman plot of the difference between the methods
against their mean (figure 4C).23 The level of bias was
214.18 and the upper and lower limits of agreement
Figure 2 Assessing the agreement between different methods of
immunohistochemical dystrophin measurement
The mean data from each method were compared in a bar chart 6 SD (A) and plotted with a
regression line (B). The difference between the Arechavala-Gomeza and Taylor methods was
plotted against their mean in a Bland-Altman plot (C) where the mean of the differences
between the methods represents the bias (i.e., the value determined by one method minus
the value determined by the other method) and the upper and lower 95% confidence limits
represent the upper and lower limits of agreement, respectively (the difference between the
2 methods should lie within these bounds on 95% of occasions).
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were 64.96 and 293.32, respectively. Although our
sample size is small, the scatter of data points in figure
4C suggests that as the mean increases, the difference
between the 2 methods also increases. Thus, while the
immunohistochemistry andWestern blotting data are
somewhat comparable, the data are not in perfect
agreement; this is unlikely to be attributable to
technical problems but rather to the different
properties of mutant dystrophin. For example, there
is a large discrepancy for sample F (patient with BMD
with a deletion of exons 10–44) with which the level
of dystrophin quantified by Western blotting is
considerably higher than that determined by
immunohistochemistry (see discussion).
DISCUSSION Dystrophin expression is being used as
a secondary outcome measure in several clinical trials,
but the lack of standardized procedures limits the
ability to compare these different studies.
We set up a study in which we first standardized
the methodologies for detecting dystrophin expres-
sion and then applied them to assess patients with
DMD and BMD. Our data show that optimized
immunohistochemistry and Western blotting were
surprisingly concordant given the variable nature of
dystrophinopathy biopsies (e.g., variable fibro-fatty
replacement between biopsies and variable dystro-
phin content within serial sections of the same
biopsy). We demonstrated that properly handled
tissue can be distributed to multiple centers
internationally to achieve comparable results. Because
recent studies demonstrated that dystrophin expres-
sion can vary between different controls, we distrib-
uted control biopsies to each laboratory.19 In the
context of clinical trials, this is a variable that will
need to be considered, either by using one set of
control samples, which may not be realistic, or the
use of humanized mouse muscle.24,25 In any case in a
clinical trial, the use of each patient’s pre- or non-
treated muscle biopsy is of paramount importance
because of the variable levels of revertant fibers and
trace dystrophin expression in each patient.15,16
Our study demonstrates that mean dystrophin
levels obtained using 3 alternative immunohisto-
chemical methods were comparable, suggesting that
when the mean dystrophin level per biopsy is re-
ported, the choice of which published script is used
is not crucial,18–20 although extra information could
be obtained with some approaches over others.26 We
have validated the robustness, in a multicentre set-
ting, of the Arechavala-Gomeza19 (5 laboratories)
and Taylor18 (3 laboratories) methods by evaluating
the precision of results generated by different equip-
ment and operators. The Beekman20 method was
only tested in one of the participating laboratories.
One limitation of this study was that the numbers
of controls and test specimens were relatively small,
because it is extremely challenging to obtain human
muscle biopsies of the size needed for such a compar-
ative study.
Figure 3 Inter- and intralaboratory variability of dystrophin quantification using Western blotting
Five laboratories each quantified the level of dystrophin expression in the same 6 biopsies using a standardized Western
blotting protocol. To assess interlaboratory variability, the mean 6 SD for each laboratory and biopsy was plotted on a
bar chart and the average coefficient of variation (CV) per laboratory calculated. To assess intralaboratory variation, the
mean 6 SD for each laboratory per sample was calculated as well as the average CV per laboratory. Laboratories are
unidentified.
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Immunohistochemistry and Western blotting
(measuring sarcolemmal and total dystrophin, respec-
tively) give information that is not necessarily identi-
cal, but rather complementary, especially in diseased
muscle. For example, in some samples (e.g., BMD
sample A, c.40_41delGA), the level of dystrophin
determined by both techniques was highly compara-
ble, while with others (e.g., BMD sample F, del ex
10–44), the level of dystrophin quantified by
Western blotting was significantly higher than that
determined by immunohistochemistry. Considering
that this patient carries a large deletion removing a
significant portion of the actin-binding domain,27,28
and the ability of this mutant dystrophin to bind to
the sarcolemma, we suggest that Western blotting in
this case overestimates the amount of functional dys-
trophin. Similar findings have been reported in trans-
genic mdx mice carrying BMD-like molecules, in
which lower levels of mini-dystrophin were observed
in the sarcolemmal Western blot fractions compared
with mice expressing full-length dystrophin.29 Con-
sidering that many BMD mutations (and the equiv-
alent DMD mutations after exon skipping) affect the
3-dimensional structure and actin-binding properties
of dystrophin,30–32 capturing both the total amount of
dystrophin in the homogenate as well as its localiza-
tion at the sarcolemma is clearly important. Assessing
dystrophin using immunohistochemistry is also
important, because a different pattern of expression
can lead to differences in the functional outcome irre-
spective of the total amount of protein present. For
example, in transgenic mdx mice, mice with a low, but
uniform dystrophin expression have a milder phenotype
than mdx mice with a higher, but variable pattern.33
Immunohistochemistry and Western blotting are
not necessarily the most novel methods for dystro-
phin quantification but they remain widely available
and accessible. Alternative, but less widely available
techniques, such as mass spectrometry34 and ELISA,
may be advantageous for detecting linear increments
of dystrophin from very small amounts of sample.
However, their use in isolation would not be desirable
because of the issues related to the functionality and
localization of mutant dystrophin discussed above.
Based on the results of our study, we recommend that
dystrophin restoration in clinical trials should be
quantified using parallel techniques, which are, in
hierarchy of importance: (1) sarcolemmal dystrophin
quantification by immunohistochemistry, and (2)
quantitative Western blotting or alternative techni-
ques measuring total dystrophin levels in muscle ho-
mogenates such as mass spectrometry. Counting
dystrophin-positive fibers is also used, but interlabor-
atory reliability has not been assessed; it currently
relies on a qualitative rather than quantitative opera-
tional definition for “positive fibers.” Nevertheless,
within a single laboratory, the reproducibility of
counting dystrophin-positive fibers has been indi-
cated, although the use of a pretreatment threshold
is paramount.7,9
Our study demonstrates that when biopsy prepa-
ration and antibody protocols are standardized, mul-
tiple laboratories are able to reliably measure
dystrophin expression using existing techniques. We
therefore recommend the use of standardized immu-
nohistochemical and Western blotting methods in
parallel as robust biochemical outcome measures for
DMD clinical trials.
Figure 4 Assessing the agreement between immunohistochemistry and
Western blotting for dystrophin quantification
The mean immunohistochemistry and Western blotting data for each biopsy were compared
in a bar chart 6 SD (A) and plotted with a regression line (B). The difference between the
methods was plotted against their mean in a Bland-Altman plot (C) where the mean of the
differences between the methods represents the bias (i.e., the value determined by one
method minus the value determined by the other method) and the upper and lower 95%
confidence limits represent the upper and lower limits of agreement, respectively (the dif-
ference between the 2 methods should lie within these bounds on 95% of occasions).
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